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Different population studies have consistently shown
that HIV-infected patients have approximately 2-fold
higher incidence of coronary artery disease or myocar-
dial infarction than non-HIV-infected persons.
However, all these studies have shown a higher preva-
lence of traditional cardiovascular risk factors (smoking,
hypertension, diabetes mellitus, and dyslipidemia) in
HIV+ relative to HIV-. These factors are the most com-
mon determinants of the cardiovascular risk in a given
HIV-infected patient. They should be screenned for in
any patient and agressively treated if estimated cardio-
vascular risk is moderate/high.
HIV infection itself additionally contributes to a
higher risk of cardiovascular disease through inflamma-
tion, immune depression (low CD4 cell counts), and
inmmune activation. There is a need to control HIV
infection with antiretroviral therapy to decrease the car-
diovascular risk associated with HIV infection. The
overall effects of any effective antiretroviral therapy on
cardiovascular disease are definitely more positive than
not giving therapy at all. Antiretroviral therapy contri-
butes to decrease the effect of HIV infection, although it
may be unable to lower it to a level similar to that of
uninfected persons.
Antiretroviral therapy may contribute to cardiovascu-
lar risk in a more modest way than that of traditional
risk factors and uncontrolled HIV infection, through the
induction of metabolic abnormalities (dyslipidemia and
insulin resistance). This effect has been proven for pro-
tease inhibitors, and it remains controversial for thymi-
dine nucleoside reverse transcriptase inhibitors. It
should be beard in mind that not all protease inhibitors
and not all patients receiving a protease inhibitor neces-
sarily develop metabolic abnormalities. It is unclear
whether antiretroviral therapy may have pathogenetic
mechanisms other than metabolic abnormalities contri-
buting for a higher cardiovascular risk.
Abacavir has been identified as a marker of cardiovas-
cular disease, but its potential role as a causative agent
is confounded by multiple factors that are impossible to
adjust for completely in cohort studies. A plausible
underlying mechanism is not known either. The results
o faB I C O M B Os u b - s t u d ys u g ested that abacavir does
not not cause inflammation, endothelial dysfunction,
hypercoagulability, or insulin resistance in virologically
suppressed HIV-infected patients. As of January 2010,
health authorities in Europe and in the United States
(EMEA and FDA, respectively) have concluded that
there is no definitive information proving that abacavir
may induce cardiovascular disease.
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